With FDA panel backing, Novo Nordisk prepares for semaglutide's potential launch
admin 19th October 2017 Uncategorised 0Novo Nordisk is one step closer to approval for semaglutide, the weekly diabetes drug it sees as a best-in-class follow-up to its blockbuster daily injection, Victoza. Next up? FDA label discussions, payer talks and prep for a market tussle with Eli Lilly’s Trulicity.
More: With FDA panel backing, Novo Nordisk prepares for semaglutide's potential launch
Source: fierce